Cite
HARVARD Citation
Moskovitz, M. et al. (2022). ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data. Oncologist. pp. e76-e84. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Moskovitz, M. et al. (2022). ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data. Oncologist. pp. e76-e84. [Online].